Back to list

Clinical experience with BIAsp 30: Results from the Indonesian cohort of the international A1chieve study

Pradana Soewondo a * , R. Bowo Pramono b, Yuanita Asri Langi c, Nanny N.M. Soetedjo d and Ida Ayu Kshanti e

Diabetes Research and Clinical Practice, pages S54 - S59

Published online Aug-2013


Article view:

Abstract

Aim

To evaluate the safety and effectiveness of biphasic insulin aspart 30 (BIAsp 30) in Indonesian patients with type 2 diabetes (T2D) as part of the 24-week, international, prospective, non-interventional A1chieve study.

Methods

Indonesian patients who started BIAsp 30 were included. Safety and efficacy was measured as part of routine clinical practice at baseline, Week 12 and Week 24. Results: Overall, 1324 patients having a mean±SD age, duration of diabetes and body mass index of 55.2±9.9 yrs, 6.8±5.2 yrs and 24.1±3.6kg/m2, respectively, were enrolled. 67% of patients were insulin-naive and 33% were prior insulin users. Glycaemic control was poor at baseline. After 24 weeks, significant reductions from baseline were observed in the mean glycated haemoglobin A1c (HbA1c) (–2.6%), fasting plasma glucose (–93.8 mg/dL) and postprandial plasma glucose (–134.8 mg/dL) levels in the entire cohort (p < 0.001). Significant reductions were also seen in insulin-naive patients and prior insulin users. At Week 24, 29.9% of patients in the entire cohort achieved target HbA1c level of <7.0%, while 26.7% and 39.2% achieved this target among insulin-naive patients and prior insulin users, respectively. The proportion of patients reporting overall hypoglycaemia significantly decreased in the entire cohort after 24 weeks of BIAsp 30 therapy. A small significant increase in body weight was noted in the entire cohort, insulin-naive patients and prior insulin users.

Conclusion

The current study suggests that BIAsp 30 can be considered as a safe and effective option for initiating as well as intensifying insulin therapy in Indonesian patients with T2D.

Keywords: Type 2 diabetes, Indonesia, Biphasic insulin aspart 30, A1chieve.


Article Outline

References

  • 1 S Soegondo, IS Widyahening, R Istantho, E Yunir. Prevalence of diabetes among suburban population of Ternate – a small remote island in the eastern part of Indonesia. Acta Med Indones. 2011;43(2):99-104
  • 2 JA Mayfield, RD White. Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function. Am Fam Physician. 2004;70:489-500
  • 3 HW Rodbard, L Blonde, SS Braithwaite, EM Brett, RH Cobin, Y Handelsman, et al., AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13(Suppl 1):1-68 Crossref.
  • 4 RC Turner, CA Cull, V Frighi, RR Holman. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005-2012 Crossref.
  • 5 SE Inzucchi, RM Bergenstal, JB Buse, M Diamant, E Ferrannini, M Nauck, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55(6):1577-1596 Crossref.
  • 6 RR Holman, SK Paul, MA Bethel, DR Matthews, HA Neil. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589 Crossref.
  • 7 AR Rolla, RE Rakel. Practical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analogues. Clin Ther. 2005;27(8):1113-1125 Crossref.
  • 8 P Valensi. Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes. Diabetes Metab Syndr Obes. 2009;2:61-71
  • 9 AJ Garber, J Wahlen, T Wahl, P Bressler, R Braceras, E Allen. Attainment of glycemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab. 2006;8(1):58-66 Crossref.
  • 10 P Home, NE Naggar, M Khamseh, G Gonzalez-Galvez, C Shen, P Chakkarwar, et al. An observational non-interventional study of patients with diabetes beginning or changed to insulin analogue therapy in non-Western countries: The A1chieve study. Diabetes Res Clin Pract. 2011;94:352-363 Abstract, Full-text, PDF, Crossref.
  • 11 P Soewondo, S Soegondo, K Suastika, A Pranoto, DW Soeatmadji, A Tjokroprawiro. The DiabCare Asia 2008 study – Outcomes on control and complications of type 2 diabetic patients in Indonesia. Med J Indones. 2010;19:235-244 Crossref.
  • 12 PH Kann, T Wascher, V Zackova, J Moeller, J Medding, A Szocs, et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes. 2006;114(9):527-532 Crossref.
  • 13 P Valensi, M Benroubi, V Borzi, J Gumprecht, R Kawamori, J Shaban, et al. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study. Int J Clin Pract. 2009;63(3):522-531 Crossref.
  • 14 WM Bebakar, CC Chow, KA Kadir, S Suwanwalaikorn, JA Vaz, OM Bech. Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9(5):724-732 Crossref.
  • 15 Y Gao, XH Guo. Switching from human insulin to biphasic insulin aspart 30 treatment gets more patients with type 2 diabetes to reach target glycosylated hemoglobin <7%: the results from the China cohort of the PRESENT study. Chin Med J (Engl). 2010;123(9):1107-1111
  • 16 D Khutsoane, SK Sharma, M Almustafa, HC Jang, ST Azar, R Danciulescu, et al. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study. Diabetes Obes Metab. 2008;10(3):212-222 Crossref.
  • 17 N Yoshioka, Y Kurihara, N Manda, K Komori, M Kato, H Kijima, et al. Step-up therapy with biphasic insulin aspart-70/30 – Sapporo 1-2-3 study. Diabetes Res Clin Pract. 2009;85(1):47-52 Crossref.
  • 18 P Raskin, E Allen, P Hollander, A Lewin, RA Gabbay, P Hu, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260-265 Crossref.
  • 19 A Esteghamati, R Rajabian, M Amini, A Bahrami, ME Khamseh, M Afkhami-Ardekani, et al. The safety and efficacy of biphasic insulin aspart 30 (BIAsp 30) in Iranians with type 2 diabetes: an open-label, non-randomised, multi-centre observational study – the Iran subgroup of the IMPROVE™ study. Endokrynol Pol. 2010;61(4):364-370

Footnotes

a University of Indonesia, Cipto Mangunkusomo Hospital, Jakarta, Indonesia University of Indonesia, Cipto Mangunkusomo Hospital, Jakarta, Indonesia

b Gadjah Mada University, Sardjito Hospital, Yogyakarta, Indonesia Gadjah Mada University, Sardjito Hospital, Yogyakarta, Indonesia

c Sam Ratulangi University, Prof. Dr. R.D. Kandou Hospital, Manado, Indonesia Sam Ratulangi University, Prof. Dr. R.D. Kandou Hospital, Manado, Indonesia

d Padjajaran University, Hasan Sadikin Hospital, Bandung, Indonesia Padjajaran University, Hasan Sadikin Hospital, Bandung, Indonesia

e Fatmawati General Hospital, Jakarta, Indonesia Fatmawati General Hospital, Jakarta, Indonesia

* Corresponding author at: University of Indonesia, Cipto Mangunkusomo Hospital, Jakarta, Indonesia. Tel.: +62 21 390 7703; fax: +62 21 392 8659

Back to list